A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the journal Blood.

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Royal Bank of Canada reiterated their sector perform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Wednesday,Benzinga reports. Royal Bank of Canada ...

KBC Group NV grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 3,862.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange ...

The drug was approved by the agency in 2023 as a treatment for paroxysmal nocturnal hemoglobinuria, winning the title of the first oral monotherapy approved for the rare blood disorder.

Urine microscopy is an important adjunct to the urinalysis. The findings of cells, casts or crystals can aid in urinalysis interpretation and in making a more accurate diagnosis. Since the formed ...

After hours: January 31 at 5:50:26 PM EST Loading Chart for OMER ...

After hours: 7:52:18 p.m. EST ...

After hours: 29 January at 18:40:00 GMT-5 ...